郑梦竹，博士，女，湖北宜昌人，华中科技大学生物药学系。研究方向为重大疾病相关靶点的药物筛选与活性评价。基于蛋白质晶体学和计算机虚拟筛选，从酶活性、细胞、动物水平评价化合物的活性，目前已得到多个先导化合物。主持国家自然科学基金青年基金、博士后面上基金及专项基金各一项。以第一/共同第一作者/共同通讯作者在Clinical and Translational Medicine、Acta Pharmaceutica Sinica B、Journal of Medicinal Chemistry、Pharmacological Research、Organic Chemistry Frontiers、Food & Function、Journal of Agricultural and Food Chemistry、Bioorganic Chemistry等杂志发表SCI论文21篇。任湖北省晶体学会副秘书长，湖北省药理学会中药药理专业委员会副秘书长，《Acta Materia Medica》杂志青年编委。
联系方式
邮箱：mengzhu_zheng@hust.edu.cn
地址：武汉市硚口区航空路13号同济医学院药学院2号楼407室邮编430030
研究方向
1.糖尿病和癌症等重大疾病的药物筛选与活性评价：基于靶点蛋白质结构的计算机虚拟筛选，从酶活性水平、细胞水平、动物水平评价化合物的活性
2.小分子靶向降解技术（PROTAC）
3.人与动物共患传染病治疗药物发现
教育与工作经历
2021/11-至今，华中科技大学讲师
2018/7-2021/10，华中科技大学，博士后
2013/9-2018/6，华中科技大学，药理学，博士
2009/9-2013/6，中南民族大学，药物制剂，学士
主持科研项目
1.国家自然科学基金青年基金,项目批准号81903863, 2020-01至2022-12
2.中国博士后科学基金,新冠肺炎疫情防控专项, 2020T130039ZX, 2020-06至2021-06
3.中国博士后科学基金,面上项目, 2019M652661, 2019-06至2021-06
参与编写书籍
1.作为数字编委编写《药理学实验教程》（十三五规划教材，中国医药科技出版社）
2.作为编委编写《微生物天然药物化学研究》（交叉学科研究生高水平课程系列教材，华中科技大学出版社）
3. Zheng M, Chen L*, Li H*. In Silico Drug Design-Chapter 17 -In Silico Modeling of FDA-Approved Drugs for Discovery of Anticancer Agents: A Drug-Repurposing Approach, Elsevier, 2019.2
主要学术论文(#Co-first author, *Correspondence author)
1.Zheng M#, Zhang Q#, Zhang C#, Wu C, Yang K, Song Z, Wang Q, Li C, Zhou Y, Chen J*, Li H*, Chen L*. A natural DYRK1A inhibitor as a potential stimulator for β-cell proliferation in diabetes.Clinical and Translational Medicine. 2021;11(7):e494.IF=11.492
2.Zheng M#, Huo J#, Gu X#, Wang Y, Wu C, Zhang Q, Wang W, Liu Y, Liu Y, Zhou X, Chen L*, Zhou Y*, Li H*. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.Journal of Medicinal Chemistry. 2021;64(11):7839-7852.IF=7.446
3.Zheng M#, Liu Y#, Wu C#, Yang K, Wang Q, Zhou Y*, Chen L*, Li H*. Novel PROTACs for degradation of SHP2 protein.Bioorganic Chemistry. 2021, 110:104788.IF=5.275
4.Zheng M#, Wu C#, Yang K, Yang Y, Liu Y, Gao S, Wang Q, Li C, Chen L*, Li H*. Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis.Pharmacological Research. 2021, 164:105367.IF=7.658
5. Wang Y#,Zheng M#, Jiang Q#, Xu Y, Zhou X, Zhang N, Sun D*, Li H*, Chen L*. Chemical Components of the Fruits of Morus nigra Linn.: Methyl Caffeate as a Potential Anticancer Agent by Targeting 3-Phosphoglycerate Dehydrogenase.Journal of Agricultural and Food Chemistry. 2021;69(42):12433-12444.IF=5.279
6. Wu C#,Zheng M#, Yang Y#, Gu X, Yang K, Li M, Liu Y, Zhang Q, Zhang P, Wang Y, Wang Q, Xu Y, Zhou Y, Zhang Y, Chen L*, Li H*. Furin: A Potential Therapeutic Target for COVID-19.iScience. 2020, 23(10):101642.IF=5.458
7. Sun W#, Wu Y#,Zheng M#, Yang Y, Liu Y, Wu C, Zhou Y, Zhang Y*, Chen L*, Li H*. Discovery of an Orally Active Small-Molecule Tumor Necrosis Factor-α Inhibitor.Journal of Medicinal Chemistry. 2020, 63(15):8146-8156.IF=7.446
8. Wu C#, Liu Y#, Yang Y#, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X*,Zheng M*, Chen L*, Li H*. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.Acta Pharmaceutica Sinica B. 2020, 10(5):766-788.IF=11.413ESI热点论文和高被引论文
9. Hu B#, Liu Y#,Zheng M#, Zhang R, Li M, Bao F, Li H*, Chen L*. Triterpenoids from Anchusa italica and their protective effects on hypoxia/reoxygenation induced cardiomyocytes injury.Bioorganic Chemistry. 2020, 97:103714.IF=5.275
10. Liu Y, Li M, Zhang Y, Wu C, Yang K, Gao S,Zheng M*, Li X*, Li H*, Chen L*. Structure based discovery of novel hexokinase 2 inhibitors.Bioorganic Chemistry. 2020, 96:103609.IF=5.275
11. Wang Q, Li M, Li C, Gu X,Zheng M*, Chen L*, Li H*. Natural Products and Derivatives Targeting at Cancer Energy Metabolism: A Potential Treatment Strategy.Current Medical Science. 2020, 40(2):205-217.IF=2.135
12. Wang Q, Zhang Q, Luan S, Yang K,Zheng M*, Li K*, Chen L*, Li H*. Adapalene inhibits ovarian cancer ES-2 cells growth by targeting glutamic-oxaloacetic transaminase 1.Bioorganic Chemistry. 2019, 93:103315.IF=5.275
13. Yang K#, Wu C#,Zheng M#, Tang R, Li X, Chen L*, Li H*. Physapubescin I from husk tomato suppresses SW1990 cancer cell growth by targeting kidney-type glutaminase.Bioorganic Chemistry. 2019, 92:103186.IF=5.275
14.Zheng M#, Guo J#, Xu J#, Yang K, Tang R, Gu X, Li H*, Chen L*. Ixocarpalactone A from dietary tomatillo inhibits pancreatic cancer growth by targeting PHGDH.Food & Function. 2019, 10(6):3386-3395.IF=5.396
15. Guo J#, Gu X#,Zheng M#, Zhang Y*, Chen L*, Li H*. Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.Bioorganic Chemistry. 2019, 87:16-22.IF=5.275
16.Zheng M#, Tang R#, Deng Y, Yang K, Chen L*, Li H*. Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.Bioorganic Chemistry. 2018, 79:89-97.IF=5.275
17.Wang J#,Zheng M#, Min Q#, Gao Y*, Sun W*. The dual regulatory function of lienal peptide on immune system.International Immunopharmacology. 2018, 55:245-253.IF=4.932
18. He Y#,Zheng M#, Li Q#,Hu Z, Zhu H, Liu J, Wang J, Xue Y*, Li H*, Zhang Y*. Asperspiropene A, a novel fungal metabolite as an inhibitor of cancer-associated mutant isocitrate dehydrogenase 1.Organic Chemistry Frontiers, 2017, 4:1137-1144.IF=5.281
19. Li W,Zheng M, Wu SP, Gao SY, Yang M, Li ZM, Min QX, Sun WG, Chen L*, Xiang G*, Li H*. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth bytargeting hexokinase 2.Journal of Experimental & Clinical Cancer Research, 2017, 36:58.IF=11.161
20. Yang Y#,Zheng M#, Liu Y, wang Y, Xu Yang, Zhou Y, Sun D*, Chen L*, Li H*. Analysis of Intermediate Hosts and Susceptible Animals of SARS-CoV-2 by Computational Methods.Zoonoses. Vol. 1(1). DOI: 10.15212/ZOONOSES-2021-0010.
